Influenza Nucleoprotein Delivered with Aluminium Salts Protects Mice from an Influenza A Virus That Expresses an Altered Nucleoprotein Sequence
Open Access
- 16 April 2013
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (4) , e61775
Abstract
Influenza virus poses a difficult challenge for protective immunity. This virus is adept at altering its surface proteins, the proteins that are the targets of neutralizing antibody. Consequently, each year a new vaccine must be developed to combat the current recirculating strains. A universal influenza vaccine that primes specific memory cells that recognise conserved parts of the virus could prove to be effective against both annual influenza variants and newly emergent potentially pandemic strains. Such a vaccine will have to contain a safe and effective adjuvant that can be used in individuals of all ages. We examine protection from viral challenge in mice vaccinated with the nucleoprotein from the PR8 strain of influenza A, a protein that is highly conserved across viral subtypes. Vaccination with nucleoprotein delivered with a universally used and safe adjuvant, composed of insoluble aluminium salts, provides protection against viruses that either express the same or an altered version of nucleoprotein. This protection correlated with the presence of nucleoprotein specific CD8 T cells in the lungs of infected animals at early time points after infection. In contrast, immunization with NP delivered with alum and the detoxified LPS adjuvant, monophosphoryl lipid A, provided some protection to the homologous viral strain but no protection against infection by influenza expressing a variant nucleoprotein. Together, these data point towards a vaccine solution for all influenza A subtypes.Keywords
This publication has 46 references indexed in Scilit:
- Recombinant protein vaccines produced in insect cellsVaccine, 2012
- Regulation of Antinucleoprotein IgG by Systemic Vaccination and Its Effect on Influenza Virus ClearanceJournal of Virology, 2011
- Vaccine adjuvants aluminum and monophosphoryl lipid A provide distinct signals to generate protective cytotoxic memory CD8 T cellsProceedings of the National Academy of Sciences, 2011
- PB2 Residue 158 Is a Pathogenic Determinant of Pandemic H1N1 and H5 Influenza A Viruses in MiceJournal of Virology, 2011
- Induction of Broadly Neutralizing H1N1 Influenza Antibodies by VaccinationScience, 2010
- Cytotoxic T Cells Are the Predominant Players Providing Cross-Protective Immunity Induced by γ-Irradiated Influenza A VirusesJournal of Virology, 2010
- Immune mechanisms of protection: can adjuvants rise to the challenge?BMC Biology, 2010
- Towards an understanding of the adjuvant action of aluminiumNature Reviews Immunology, 2009
- Age-related trends in the timeliness and prediction of medical visits, hospitalizations and deaths due to pneumonia and influenza, British Columbia, Canada, 1998–2004Vaccine, 2008
- Replication fitness determines high virulence of influenza A virus in mice carrying functional Mx1 resistance geneProceedings of the National Academy of Sciences, 2007